Drugs / rgp120/HIV-1IIIB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00001021 | — | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rgp120/HIV-1IIIB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001021 ↗ |
| Known as | IIIB rgp120 vaccine | “MN rgp120 vaccine and IIIB rgp120 vaccine are both prepared by recombinant DNA technology.” NCT00001021 ↗ |
| Known as | IIIB rgp120/HIV-1 vaccine | “IIIB rgp120/HIV-1 vaccine” NCT00001021 ↗ |
| Modality | Vaccine | “IIIB rgp120/HIV-1 vaccine” NCT00001021 ↗ |
| Route | Intramuscular | “Immunizations (or placebo injections) are given intramuscularly at 0, 4, 24, and 48 weeks.” NCT00001021 ↗ |